The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC

被引：1

作者：

Ardeshir-Larijani, Fatemeh ^{[1
]}

Ramalingam, Suresh S. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 11期

关键词：

D O I：

10.1038/s41571-024-00938-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.

引用

页码：767 / 768

页数：2

共 50 条

[31] Rociletinib-associated cataracts in EGFR-mutant NSCLC.
Piotrowska, Zofia
Liu, Erica
Logan, Jennifer
Chow, Jessica
Woreta, Fasika A.
Muzikansky, Alona
Stober, Lisa
Wanat, Alexandra Carly
Goodwin, Kelly
Azzoli, Christopher G.
Temel, Jennifer S.
Heis, Rebecca Suk
Shaw, Alice Tsang
Engelman, Jeffrey A.
Kopani, Kamden
Sequist, Lecia V.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[32] Characteristics and outcomes of Latino patients with EGFR-mutant NSCLC.
Mathew, Matthen
Lagos, Galina G.
Rao, Nisha
Asmar, Ramsey Nicholas
Liu, Xinhua
Rizvi, Naiyer A.
Orjuela, Manuela A.
Shu, Catherine A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?
Cheng, Michael L.
Oxnard, Geoffrey R.
CLINICAL CANCER RESEARCH, 2019, 25 (03) : 899 - 900
[34] Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC
Mehta, Pareen
Hamid, Omid
Klempner, Samuel J.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : 1857 - 1858
[35] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
Kian, W.
Roisman, L. C.
Dudnik, J.
Chernomordikov, L.
Allen, A. M.
Corn, B.
Dudnik, E.
Rosenberg, S. K.
Zemel, M.
Lavrenkov, K.
Peled, N.
ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
[36] Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC
Klempner, Samuel J.
Hata, Aaron N.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : 1875 - 1877
[37] Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA
Lee, S. -H.
Cho, B. C.
Hayashi, H.
Felip, E.
Spira, A. I.
Girard, N.
Kim, Y. J.
Ostapenko, Y.
Danchaivijitr, P.
Liu, B.
Alip, A.
Korbenfeld, E.
Mourao Dias, J.
Lee, K. H.
Xiong, H.
How, S. H.
Cheng, Y.
Chang, G. -C.
Yang, J. C. -H.
Besse, B.
Thomas, M.
Curtin, J. C.
Zhang, J.
Xie, J.
Sun, T.
Martinez, M.
Sethi, S.
Knoblauch, R. E.
Fennema, E.
Daksh, M.
Ennis, M.
Bauml, J. M.
Lu, S.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S12 - S12
[38] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
Shreeve, S. M.
Martinez, M.
Verheijen, R. B.
Xie, J.
Sun, T.
Haddish-Berhane, N.
Curtin, J. C.
Karkera, J.
Pang, D.
Roshak, A.
Knoblauch, R. E.
Patel, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
[39] The Usefulness of Liquid Biopsy for ctDNA in Patients with EGFR-Mutant NSCLC During and After Treatment with EGFR-TKIs
Yokoyama, T.
Naka, G.
Ishida, H.
Kishi, K.
Ohashi, Y.
Kunitoh, H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
[40] Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
Sun, Li
Guo, Yi-Jia
Song, Jun
Wang, Yan-Ru
Zhang, Shu-Ling
Huang, Le-Tian
Zhao, Jian-Zhu
Jing, Wei
Han, Cheng-Bo
Ma, Jie-Tao
FRONTIERS IN ONCOLOGY, 2021, 10

← 1 2 3 4 5 →